Valued at a\u00a0market cap of $71.8 billion, Boston Scientific Corporation (BSX) develops, manufactures, and markets minimally invasive medical devices and therapies. The Marlborough, Massachusetts-based company specializes in creating highly engineered medical technologies used across a broad spectrum of subspecialties to diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions.<\/p>\n
Companies worth $10 billion or more are typically classified as \u201clarge-cap stocks,\u201d and BSX fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the medical devices industry. The company\u2019s primary strength lies in its “category leadership” strategy, which focuses heavily on high-growth, procedure-heavy medical fields where it can establish dominant, clinically differentiated positions rather than attempting to be a generalist hospital supplier.<\/p>\n
More News from Barchart <\/p>\n
Despite its notable strength, this\u00a0healthcare company\u00a0has slipped 56.2% from its\u00a052-week high of $109.50, reached on Sep. 9, 2025. Moreover, shares of\u00a0BSX\u00a0have\u00a0declined 37.6% over the past three months, notably underperforming the State Street Health Care Select Sector SPDR ETF\u2019s (XLV)\u00a07.7% drop during the same time frame.<\/p>\n
www.barchart.com <\/p>\n
In the longer term, BSX\u00a0has fallen 54.4%\u00a0over the past 52 weeks, notably lagging XLV’s 11.5% uptick over the same time period. Additionally, on a YTD basis, shares of BSX are down 49.7%, compared to XLV\u2019s 4.5% loss.<\/p>\n
To confirm its bearish trend, BSX has been\u00a0trading below its 200-day moving average since mid-November 2025, with slight fluctuations, and has remained below its 50-day moving average since early December.<\/p>\n
www.barchart.com <\/p>\n
On Apr. 24, shares of BSX\u00a0fell 5.5% after its\u00a0Q1 earnings release, despite posting\u00a0better-than-expected results. The company\u2019s revenue rose 11.6% year-over-year to $5.2 billion and marginally surpassed the Wall Street estimates. Moreover, its adjusted EPS reached $0.80, which also came in ahead of analyst estimates. However, investor confidence was shaken as the company lowered its full-year outlook due to intensifying cardiac market competition.<\/p>\n
In the competitive arena of medical devices, BSX has also lagged its rival, Stryker Corporation (SYK), which\u00a0dropped 21.7% over the past 52 weeks and 14.8% on a YTD basis.<\/p>\n
Despite BSX\u2019s recent underperformance, analysts remain highly optimistic about its prospects.\u00a0The stock has a consensus rating of “Strong Buy\u201d from the 31 analysts covering it, and the\u00a0mean price target of $81.44 suggests a 69.7% premium to its current price levels.<\/p>\n
On the date of publication, Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on Barchart.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Valued at a\u00a0market cap of $71.8 billion, Boston Scientific Corporation (BSX) develops, manufactures, and markets minimally invasive medical…\n","protected":false},"author":2,"featured_media":479386,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[68450,206669,103,397,396,61,60,3883],"class_list":["post-479385","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-boston-scientific","tag-broad-spectrum","tag-health","tag-health-care","tag-healthcare","tag-ie","tag-ireland","tag-medical-devices"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/479385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/comments?post=479385"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/posts\/479385\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media\/479386"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/media?parent=479385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/categories?post=479385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/ie\/wp-json\/wp\/v2\/tags?post=479385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}